Patents by Inventor Michael D. Kaplan

Michael D. Kaplan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240101704
    Abstract: The invention relates generally to multispecific polypeptides having constrained CD3 binding. In some embodiments, the multispecific polypeptides contain cleavable linkers that, when cleaved, results in dual effector functions. Also provided are methods of making and using these multispecific polypeptides in a variety of therapeutic, diagnostic and prophylactic indications.
    Type: Application
    Filed: November 27, 2023
    Publication date: March 28, 2024
    Applicant: Inhibrx, Inc.
    Inventors: Brendan P. ECKELMAN, Michael D. KAPLAN, Katelyn M. WILLIS, Quinn DEVERAUX, John C. TIMMER
  • Patent number: 11866507
    Abstract: The invention relates generally to multispecific polypeptides having constrained CD3 binding. In some embodiments, the multispecific polypeptides contain cleavable linkers that, when cleaved, results in dual effector functions. Also provided are methods of making and using these multispecific polypeptides in a variety of therapeutic, diagnostic and prophylactic indications.
    Type: Grant
    Filed: April 11, 2018
    Date of Patent: January 9, 2024
    Assignee: Inhibrx, Inc.
    Inventors: Brendan P. Eckelman, Michael D. Kaplan, Katelyn M. Willis, Quinn Deveraux, John C. Timmer
  • Publication number: 20230348600
    Abstract: Provided herein are binding polypeptides that specifically bind CD28. More specifically, provided herein are fusion proteins, including multivalent and/or multispecific constructs that bind at least CD28. Also provided are pharmaceutical compositions containing the polypeptides, nucleic acid molecules encoding the polypeptides and vectors thereof, and methods of use and uses of the provided CD28 binding polypeptides for treating diseases and conditions, such as cancer.
    Type: Application
    Filed: January 28, 2021
    Publication date: November 2, 2023
    Applicant: Inhibrx, Inc.
    Inventors: John C. TIMMER, Rutger H. JACKSON, Katelyn M. WILLIS, William S. CRAGO, Michael D. KAPLAN, Brendan P. ECKELMAN
  • Publication number: 20230295336
    Abstract: The invention relates generally to multispecific polypeptides having constrained CD3 binding. In some embodiments, components of the multispecific polypeptides are connected by a non-cleavable linker. Also provided are methods of making and using these multispecific polypeptides in a variety of therapeutic, diagnostic and prophylactic indications.
    Type: Application
    Filed: June 6, 2023
    Publication date: September 21, 2023
    Applicant: Inhibrx, Inc.
    Inventors: Brendan P. ECKELMAN, Michael D. KAPLAN, Katelyn M. WILLIS, John C. TIMMER
  • Publication number: 20230124851
    Abstract: Provided herein are binding polypeptides that specifically bind B7H3. More specifically, provided herein are fusion proteins, including multivalent and/or multispecific constructs and chimeric antigen receptors, that bind B7H3. Also provided are pharmaceutical compositions containing the polypeptides, nucleic acid molecules encoding the polypeptides and vectors and cells thereof, and methods of use and uses of the provided B7H3 binding polypeptides for treating diseases and conditions, such as cancer.
    Type: Application
    Filed: October 9, 2019
    Publication date: April 20, 2023
    Applicant: Inhibrx, lnc.
    Inventors: Brendan P. ECKELMAN, Michael D. KAPLAN, Katelyn M. WILLIS, Kyle S. JONES, Angelica N. SANABRIA, Sydney A. BARNES, Margaret E. HAERR, John C. TIMMER
  • Publication number: 20210380679
    Abstract: Provided herein are binding polypeptides that specifically bind DLL3. More specifically, provided herein are fusion proteins, including multivalent and/or multispecific contracts and chimeric antigen receptors, that bind DLL3. Also provided are pharmaceutical compositions containing the polypeptides, nucleic acid molecules encoding the polypeptides and vectors and cells thereof, and methods of use and uses of the provided DLL3 binding polypeptides for treating diseases and conditions, such as cancer.
    Type: Application
    Filed: October 9, 2019
    Publication date: December 9, 2021
    Applicant: Inhibrx, Inc.
    Inventors: Brendan P. ECKELMAN, Michael D. KAPLAN, Kateiyn M. WILLIS, Raiay A. PANDIT, Angelica N. SANABRIA, Sydney A. BARNES, Margaret E. HAERR, John C. TIMMER
  • Publication number: 20210340273
    Abstract: Provided herein arm binding polypeptides that specifically bind 5T4. More specifically, provided herein are fusion proteins, including multivalent and/or multispecific constructs and chimeric antigen receptors, that bind 5T4. Also provided are pharmaceutical compositions containing the polypeptides, nucleic acid molecules encoding the polypeptides and vectors and cells thereof, and methods of use and uses of the provided 5T4 binding polypeptides for treating diseases and conditions, such as cancer.
    Type: Application
    Filed: October 9, 2019
    Publication date: November 4, 2021
    Applicant: Inhlbrx, inc.
    Inventors: John C. TIMMER, Michael D. KAPLAN, Katelyn M. WILLIS, Raiay A. PANDIT, Angelica N. SANABRIA, Sydney A. BARNES, Margaret E. HAERR, Brendan P. ECKELMAN, Rutger H. JACKSON
  • Publication number: 20200048350
    Abstract: The invention relates generally to multispecific polypeptides that bind at least CD3, a second antigen, and a receptor of a T cell, such as a costimulatory receptor or an inhibitory receptor, in which the multispecific polypeptide constructs are able to engage CD3. In some embodiments, the multispecific polypeptide constructs bind a costimulatory receptor and provide costimulatory binding activity. In some embodiments, the multispecific polypeptide constructs bind an inhibitory receptor and block inhibitory activity. In some aspects, the multispecific polypeptides have constrained CD3 binding and bind to or engage CD3 only upon binding to the second antigen, such as a tumor associated antigen. In some embodiments, the multispecific polypeptides contain cleavable linkers that, when cleaved, result in dual effector functions. Also provided are methods of making and using these multispecific polypeptides in a variety of therapeutic, diagnostic and prophylactic indications.
    Type: Application
    Filed: July 23, 2019
    Publication date: February 13, 2020
    Applicant: Inhibrx, Inc.
    Inventors: Brendan P. ECKELMAN, Michael D. KAPLAN, Katelyn M. WILLIS, Quinn DEVERAUX, Kyle S. JONES, Rajay A. PANDIT, John C. TIMMER
  • Publication number: 20190330366
    Abstract: The invention relates generally to multispecific polypeptides having constrained CD3 binding. In some embodiments, components of the multispecific polypeptides are connected by a non-cleavable linker. Also provided are methods of making and using these multispecific polypeptides in a variety of therapeutic, diagnostic and prophylactic indications.
    Type: Application
    Filed: April 10, 2019
    Publication date: October 31, 2019
    Applicant: Inhibrx, Inc.
    Inventors: Brendan P. ECKELMAN, Michael D. KAPLAN, Katelyn M. WILLIS, John C. TIMMER
  • Publication number: 20190010242
    Abstract: The invention relates generally to multispecific polypeptides having constrained CD3 binding. In some embodiments, the multispecific polypeptides contain cleavable linkers that, when cleaved, results in dual effector functions. Also provided are methods of making and using these multispecific polypeptides in a variety of therapeutic, diagnostic and prophylactic indications.
    Type: Application
    Filed: April 11, 2018
    Publication date: January 10, 2019
    Applicant: Inhibrx, Inc.
    Inventors: Brendan P. ECKELMAN, Michael D. KAPLAN, Katelyn M. WILLIS, Quinn Deveraux, John C. Timmer
  • Publication number: 20070282271
    Abstract: The device protects the proximal extension of an indwelling catheter and its percutaneous puncture site from moisture, fluids and risk of infection and maintains a clean environment and a fluid-impermeable and bacteria growth-inhibiting seal against the patient's skin when bathing, showering or swimming, and also protects others from being exposed to the patient's blood and catheter at that time. A faceplate is adhered to the skin about the catheter exit site with medical adhesive, the proximal end of the catheter is secured to the faceplate to prevent it from moving from within the patient's body, and a water-impermeable housing is sealed to the faceplate, with the proximal end of the catheter extending into a cavity of the housing. An antimicrobial material may be disposed on the backside of the faceplate. The device allows a patient to shower, bathe and swim while preventing the catheter from being dislodged from the patient.
    Type: Application
    Filed: May 31, 2006
    Publication date: December 6, 2007
    Inventors: Michael D. Kaplan, Cornelius McCarthy, Steven M. Kaplan